LAM561 as add-on may delay glioblastoma disease progression
Adding the investigational therapy LAM561 to standard of care treatment may delay disease progression or death in people with newly diagnosed glioblastoma whose tumors exhibit…
News
Study of NKT3964 in gynecological, other cancers advances
A Phase 1 clinical trial testing Nikang Therapeutics’ oral therapy NKT3964 in people with certain advanced or metastatic solid tumors, including gynecological cancers,…
Use of dexamethasone may manage Tecvayli’s immune side effect: Study
The use of dexamethasone alone may successfully treat the immune side effect cytokine release syndrome (CRS) in people with relapsed or refractory multiple…
Olverembatinib named ALL breakthrough therapy in China
China has granted breakthrough therapy designation to olverembatinib to be used with low-intensity chemotherapy as a first-line treatment for newly diagnosed people with Philadelphia chromosome-positive…
SIL204 reduces tumors, slows spread in pancreatic cancer models
Administering Silexion Therapeutics‘ investigational therapy SIL204 under the skin effectively reduced the growth of primary tumors and their metastatic spread to various organs in…
Pediatric spinal glioma tumor gene alterations hint at therapeutic target
Tumors in children with aggressive gliomas that formed in the spinal cord all exhibited genetic changes that might be able to be targeted therapeutically,…
Swollen lymph node leads to fallopian tube cancer diagnosis
In a rare case, a woman in China was found to have fallopian tube cancer in her left tube that had spread to lymph nodes…
March’s Myeloma Action Month means sharing patient milestones
This year’s Myeloma Action Month (MAM), which is observed each March, is focused on celebrating and sharing patient milestones to help call…
EU committee recommends Jaypirca for certain leukemia patients
A European Medicines Agency (EMA) committee recommended that Jaypirca (pirtobrutinib) be approved to treat some adult patients with chronic lymphocytic leukemia (CLL), a type of…
Immunotherapy shows promise as treatment for pancreatic cancer
Treatment with CAN-2409, an immune-modulating anticancer therapy, showed promising trends toward improved survival in a Phase 2 clinical trial involving people with pancreatic cancer,…
